z-logo
Premium
γ‐sarcoglycan and dystrophin mutation spectrum in an Algerian cohort
Author(s) -
Dalichaouche Imene,
Sifi Yamina,
Roudaut Carinne,
Sifi Karima,
Hamri Abdelmadjid,
Rouabah Leila,
Abadi Noureddine,
Richard Isabelle
Publication year - 2017
Publication title -
muscle and nerve
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.025
H-Index - 145
eISSN - 1097-4598
pISSN - 0148-639X
DOI - 10.1002/mus.25443
Subject(s) - mutation , dystrophin , cohort , medicine , genetics , biology , duchenne muscular dystrophy , gene
We report the genetic analysis of a large series of 76 Algerian patients from 65 unrelated families who presented with early onset severe muscular dystrophy and a clinical phenotype resembling limb‐girdle muscular dystrophy type 2C. Methods To define the genetic basis of the diseases in these families, we undertook a series of analyses of the γ‐sarcoglycan ( SGCG ) and DMD genes. Results Fifteen families were shown to carry SGCG variants. Only 2 kinds of causative mutations were identified in the population, mostly in the homozygous state: the well‐known c.525delT and the previously described c.87dupT. In the DMD gene, 12 distinctive patterns of deletion were identified, mostly affecting the dystrophin central region. Conclusions Our data suggest that a simple molecular screen consisting of 2 allele‐specific polymerase chain reactions (PCRs) and a set of 3 multiplex PCRs can diagnose half of the patients who present with progressive muscular dystrophy in the developing nation of Algeria. Muscle Nerve 56 : 129–135, 2017.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom